Stocktoria
INOVIO PHARMACEUTICALS, INC. INO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1998-12-08
INOVIO PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65,343 | $217,756 | $832,010 | $10.3M | $1.8M |
| R&D expense | $54.2M | $75.6M | $86.7M | $187.7M | $249.2M |
| Operating income | -$86.8M | -$112.4M | -$143.9M | -$267.6M | -$301.2M |
| Interest expense | — | — | $1.2M | $1.3M | $1.9M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$84.9M | -$107.3M | -$135.1M | -$279.8M | -$303.7M |
| EPS (diluted) | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-17.45 |
| Operating cash flow | -$88.6M | -$104.1M | -$124.4M | -$216.2M | -$215.7M |
| Free cash flow | -$88.9M | -$104.6M | -$124.7M | -$217.2M | -$216.9M |
| Cash & equivalents | $44.3M | $65.8M | $14.3M | $46.3M | $71.1M |
| Total assets | $74.3M | $113.2M | $171.0M | $348.5M | $495.9M |
| Total liabilities | $50.2M | $44.7M | $53.6M | $126.2M | $96.3M |
| Shareholders' equity | $24.1M | $68.5M | $117.3M | $222.4M | $399.7M |
Source: SEC EDGAR filings · CIK 0001055726 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.